title: Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
abstract: An established model of arterial injury was used to evaluate the ability of the glycoprotein (GP) IIb/IIIa antagonist abciximab to inhibit platelet function and deter thrombus formation in cats. The study was a blinded evaluation, with control cats receiving aspirin and placebo and treatment cats receiving aspirin plus abciximab. The group treated with aspirin plus abciximab had significantly (P<.05) less thrombus formation based on a smaller number and frequency of cyclic flow reductions and reduced luminal thrombus area than cats treated with aspirin plus placebo. Abciximab administered in addition to aspirin also resulted in significant (P<.05) inhibition of platelet function based on mucosal bleeding time and change in bleeding time from baseline.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
authors.forename: Janice McIntosh
authors.initials: JM
authors.lastname: Bright
authors.forename: Kristy
authors.initials: K
authors.lastname: Dowers
authors.forename: Barbara E
authors.initials: BE
authors.lastname: Powers
mesh_terms: D000077284:Abciximab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001158:Arteries / Q000187:drug effects / Q000293:injuries*; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D002371:Cat Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D002415:Cats; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D013927:Thrombosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000662:veterinary*; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D001241:Aspirin; D000077284:Abciximab